氨磺必利与奥氮平治疗精神分裂症首次发病患者的对照研究

摘要

目的：比较氨磺必利和奥氮平治疗精神分裂症的临床疗效和安全性。方法：将62例精神分裂症首次发病患者随机分为氨磺必利组和奥氮平组治疗8周。采用阳性与阴性症状量表（PANSS）于治疗前后评定疗效，并观察不良反应。结果：治疗8周两组 PANSS 总分减分及一般病理学减分比较差异无统计学意义；氨磺必利组 PANSS 阴性症状减分明显高于奥氮平组，奥氮平组 PANSS 阳性症状减分显著高于氨磺必利组（P 均﹤0.02）。氨磺必利组和奥氮平组总有效率分别为93.2%和96.8%，差异无统计学意义（P ﹥0.02）。奥氮平组体质量增加、镇静嗜睡和血糖升高发生率明显高于氨磺必利组（P ﹤0.02或 P ﹤0.01）。结论：氨磺必利治疗精神分裂症的疗效与奥氮平相当，但不良反应相对较少。%Objective:To compare the clinical efficacy and safety of amisulpride and olanzapine in first episode patients with schizophrenia. Method:Sixty-two first episode patients with schizophrenia were divided randomly into amisulpride group and olanzapine group,and received amisulpride and olanzapine respectively for 8 weeks. The positive and negative symptoms scale(PANSS)was used before and after treatment to evaluate the efficacy,and the side effects were observed. Results:After 8 weeks of treatment,the reduction of PANSS total score and general pathology score between the two groups were not statistically significant;the reducion of nega-tive symptoms score in amisulpride group was significantly higher than olanzapine group,while the reducion of positive symptoms score in olanzapine group was significantly higher than amisulpride group(all P ﹤ 0. 02). The total efficiency in amisulpride group and olanzapine group were 93. 2% and 96. 8% respectively,and no signifi-cant difference between two groups(P ﹥ 0. 02). The incidence of sedation or somnolence,weight gain and glu-cose enhance in olanzapine group were higher than the amisulpride group(P ﹤0. 02 or P ﹤0. 01). Conclusion:Amisulpride is as effective as olanzapine for schizophrenia,but amisulpride has fewer side effects.